Healthcare
iRhythm Technologies, Inc.(IRTC)
Live Price
Offline$104.65
+2.81% today
1Y Change
-27.30%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $3.96B
- Revenue Growth
- +26.2%
- EPS Growth
- +61.7%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
iRhythm Technologies, Inc. (IRTC) is a Healthcare stock with a market cap of $3.96B and listed on NASDAQ. The stock last traded around $104.65 and down 27.3% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +26.2%, EPS growth of +61.7%, a dividend yield of 0.0%. What stands out right now is revenue +26.2%, EPS +61.7%, free cash flow +213.0% with operating margin -4.4% and ROIC -3.9%. Valuation sits in the middle of the pack at price/sales 5.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IRTC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+26.2% vs +7.6% peer median
Operating Margin
Below sector median
-4.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +26.2% and EPS at +61.7%, with operating margin around -4.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | -3.4% | -8.6% | -13.4% |
2026 Feb 19, 2026 | +750.0% | -5.0% | -11.8% | -25.9% |
2025 Oct 30, 2025 | +83.3% | +1.7% | -3.6% | +2.1% |
Benchmark Edge
IRTC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IRTC
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IRTC Max Drawdown
-46.21%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IRTC and SPY.
Company Overview
iRhythm Technologies, Inc.
NASDAQ Global Select
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
- Leadership
- Quentin S. Blackford
- IPO Date
- Oct 20, 2016
- Employees
- 2.0k
- Street Address
- 699 8th Street
- Mailing
- San Francisco, CA, 94103
- Region
- San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 415 632 5700
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 5.0
- Price/Book
- 24.3
Growth
- Revenue
- +26.2%
- EPS
- +61.7%
- Free Cash Flow
- +213.0%
Profitability
- Gross Margin
- 71.0%
- Operating Margin
- -4.4%
- Net Margin
- -3.5%
- ROE
- -20.6%
- ROIC
- -3.9%
Balance Sheet
- Debt/Equity
- 4.52
- Current Ratio
- 5.17
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.